The FK506 binding protein 51 (FKBP5), an intrinsic regulator of the glucocorticoid receptor, has been associated with pathological behaviors particularly in the context of childhood trauma (CT), via a putatively regulatory polymorphism, rs1360780. However, trans-and cis-acting effects of this locus and its interaction with CT are incompletely understood. To study its effects on the expression of glucocorticoid-regulated genes including FKBP5, we used lymphoblastoid cell lines (LCLs) derived from 16 CT-exposed patients with greater than two substance dependence/suicidal behavior diagnoses (casesCT+) and 13 non-CT-exposed controls (controlsCT−). This study in LCLs measures long-term trait-like differences attributable to genotype or lasting epigenetic modification. Through analysis of differential allelic expression (DAE) using an FKBP5 3 ′ -UTR reporter single nucleotide polymorphism (SNP), rs3800373, that is in strong linkage disequilibrium with rs1360780, we confirmed that the rs1360780 risk allele (A) (or conceivably that of a linked SNP) leads to higher FKBP5 expression in controlsCT−. Intriguingly, casesCT+ did not show DAE, perhaps because of a genotype-predicted difference in FKBP5 DNA methylation restricted to casesCT+. Furthermore, through correlation analyses on FKBP5 expression at baseline and after induction by dexamethasone, we observed that casesCT+ had lower induction of FKBP5 expression, indicating that overall they may have strong ultra-short negative-feedback. Only casesCT+ showed an effect of rs1360780 genotype on expression of FKBP5 and other glucocorticoid-regulated genes. Together, these results confirm that the rs1360780 locus alters FKBP5 expression and further that in trans-fashion this locus affects the expression of other glucocorticoid-regulated genes after a glucocorticoid challenge. The CT exposure appears to be essential for trans-effects of rs1360780 on glucocorticoid-regulated genes.
Stress stimulates the hypothalamus to release corticotropin releasing factor (CRF). The CRF induces pituitary gland secretion of adrenocorticotropic hormone (ACTH), which stimulates the adrenal gland to release cortisol. The principal target of cortisol is the glucocorticoid receptor (GR). The activity of this receptor is regulated by an ultra-short negative-feedback loop (Sapolsky et al. 2000) . Prolonged or excessive activation of the GR, which can occur when this feedback loop is impaired and following stress, has been implicated in the pathogenesis of mood and anxiety disorders (Holsboer 2000; Pariante & Miller 2001) .
The FK506 binding protein 51 (FKBP5) is a critical negative regulator of GR function. Binding of FKBP5 to the GR reduces its cortisol-binding capacity and prevents nuclear translocation (Binder 2009 , Denny et al. 2000 Jaaskelainen et al. 2011; Wochnik et al. 2005) . The GR activation rapidly enhances FKBP5 gene expression, reducing GR sensitivity (Binder 2009 ). There is strong linkage disequilibrium (LD) across the FKBP5 gene including in individuals of African descent as shown in HapMap and in our earlier study (Roy et al. 2010) . Haplotypes including the single nucleotide polymorphisms (SNPs) rs1360780, rs9296158, rs3800373 and rs9470080 have been shown to interact with childhood trauma (CT) to predict post-traumatic stress disorder (PTSD), suicide attempts and major depression (Appel et al. 2011; Binder et al. 2004 Binder et al. , 2008 Koenen et al. 2005; Mehta et al. 2011; Roy et al. 2010; Zimmermann et al. 2011) . The rs1360780 (A/G) SNP is adjacent to a functional glucocorticoid response element (GRE). It has been reported to be a cis-acting variant affecting FKBP5 expression and GR sensitivity (Klengel et al. 2013) . In healthy individuals, the risk allele (A) has been associated with higher FKBP5 expression and relatively reduced GR sensitivity as well as impaired recovery of cortisol levels in response to stress (Binder et al. 2004 (Binder et al. , 2008 . Moreover, risk allele carriers exposed to CT showed less DNA methylation near and at functional GREs of the FKBP5 gene (Klengel et al. 2013) . Nevertheless, the functionality of rs1360780 and its interaction with stress exposure is not yet fully understood.
Our study was performed in lymphoblastoid cell lines (LCLs) derived from an African American male sample of substance-dependent patients exposed to CT (casesCT+) and healthy controls who had not experienced CT (controlsCT−). We investigated the way in which cis-or trans-acting functionality of rs1360780 genotypes affects not only FKBP5 expression but also expression of other glucocorticoid-regulated genes. We analyzed differential allelic expression (DAE) in casesCT+ and controlsCT−, who were heterozygous for both rs1360780 (A/G) in intron2 and rs3800373 (G/T) in the 3 ′ -UTR. As mentioned earlier, rs3800373 is strongly linked with rs1360780 in African ancestry individuals (r 2 = 0.88, D ′ = 1.0) in the HapMap project database. Moreover, in our previous study of these African Americans, the haplotypes including SNPs rs1360780 (A/G) and rs3800373 (G/T) are AG and GT with high frequencies ≈0.38 and ≈0.57, respectively (Roy et al. 2010) . Therefore, the effect of rs1360780 on FKBP5 expression would be easily detected by allelic difference at the reporter SNP rs3800373.
Furthermore, we investigated whether genotypes and CT influence expression of glucocorticoid-regulated genes after GR stimulation to identify genotype-induced GR resistance and to dissociate allele-specific effects from long-lasting changes in FKBP5 expression because of trauma-induced methylation of regulatory CpGs. In summary, in this study we investigated DAE, the combined influences of genotype and CT on FKBP5 expression at baseline and after GR stimulation, the influence of FKBP5 rs1360780 on other glucocorticoid-regulated genes after GR stimulation and finally the influence of genotype and CT on DNA methylation at the intron 2 and intron 7 regulatory regions of FKBP5, as previously described (Klengel et al. 2013 ).
Materials and methods

Participants
A detailed description of this sample has previously been provided (Roy et al. 2010 ). All participants gave written informed consent to the study that was approved by the Institutional Review Boards of the Department of Veteran Affairs New Jersey Healthcare System (VANJHCS) and the University of Medicine and Dentistry, New Jersey Medical School. Patients (90% men) were recruited from the Substance Abuse Treatment Program at the VANJHCS and were interviewed using the substance abuse section of the Structured Clinical Interview for DSM-IV to establish lifetime diagnoses. Patients had single or comorbid diagnoses of alcohol, cocaine or heroin addiction and a significant proportion had attempted suicide. Controls (40% men) were recruited from the same geographical area as the patients and were free of any lifetime alcohol or drug use disorder or suicide attempt. Participants completed the 28-item version of the Childhood Trauma Questionnaire (CTQ). The total CTQ score ranges from 25 to 125. Because of sample size issues, only LCLs from male participants were included in the current analysis. A total of 278 male patients and 72 controls had both DNA and CTQ data available. The total CTQ score ranged from 25 to 110; the mean (SE) score was 48.6 (1.0) for patients and 38.0 (2.0) for controls. Low and high CT groups were selected out of the total samples: a low CT group of controls (controlsCT−); (n = 13) with total CTQ score < 40 (mean: 31.5 ± 4.9); a high CT group of cases (casesCT+) defined as patients (n = 16) with total CTQ > 60 (mean: 74.1 ± 11.2) and with an average of two psychiatric disorders (alcohol, cocaine, heroin addiction, suicide attempt) ( Table 1 ). The pyrosequencing study was carried out at a later date and at that time four more suitable LCLs became available: one controlCT−, rs1360780 GG, CTQ score = 33; three casesCT+: rs1360780 GG, CTQ scores = 65, 91; rs1360780 AA, CTQ score = 67.
The participants whose LCLs were included in the current analysis had been genotyped for ancestry informative markers from which ethnic factor scores had been derived (Roy et al. 2010) . There was no difference between casesCT+ and controlsCT− in African ancestry: mean (SE) = 0.79 (0.03) vs. 0.80 (0.03), respectively, P = 0.74.
TaqMan genotyping of samples for FKBP5 rs1360780 and rs3800373
The rs1360780 and rs3800373 SNPs were obtained as a TaqMan Assays-on-Demand (C___8852038_10; C__27489960_10), respectively (Applied Biosystems, Foster City, CA, USA). Genotyping was performed according to the manufacturer's protocol and allelic discrimination genotype determined at end-point using ABI 7900HT Sequence Detection System 2.4. Genotyping accuracy was determined empirically by duplicate genotyping of 25% of the samples selected randomly. The error rate was <0.005, and the completion rate was >0.95.
Lymphoblastoid cell lines (LCLs)
LCLs derived from peripheral blood B cells transformed with Epstein Barr Virus and were maintained in culture for a minimum of 50 passages. The LCLs were grown at 37 ∘ C and 5% CO 2 in RPMI-1640 steroid-free medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 0.1 mg/ml streptomycin, and 100 IU/ml penicillin.
Quantitative RT-PCR
To study the expression of FKBP5, FKBP4 and other glucocorticoid-regulated genes, we performed quantitative reverse transcription polymerase chain reaction (RT-PCR) with primers (Table S1 , Supporting Information) for FKBP5, FKBP4, three other known glucocorticoid-regulated genes; TSC22D3 (TSC22 domain family member 3), BIM (BCL-2-interacting mediator of cell death) and RUNX2 (Runt-related transcription factor 2) (Frodl et al. 2012; Heidari et al. 2012) , and four genes, LTF (lactotransferrin), MSL3L1 (male-specific lethal 3 homolog (Drosophila)), ARG1 (arginase 1) and PHF21A (PHD finger protein 21A), which have been proposed to be glucocorticoid-regulated (Klengel et al. 2013; Menke et al. 2012) . The RNA was extracted with TRIzol (Thermo Scientific, Waltham, MA, USA) from untreated cells or following treatment with dexamethasone (Dex, 100 nM) (D4902, Sigma-Aldrich Chemie, Steinheim, Germany) for 24 h. Residual genomic DNA contamination was removed by incubation with DNaseI (Thermo Scientific) at 37 ∘ C for 30 min. Total RNA was reverse-transcribed into cDNA with the High Capacity cDNA reverse transcription kit (Applied Biosystems) according to the protocols. For quantitative PCR, 1 μl of cDNA was mixed with gene-specific primers (0.25 μM final concentration), 2× SYBR Green master mix (Applied Biosystems) in a 10 μl volume. Reactions were carried out on the ABI 7900 real-time PCR system with the following protocol: one cycle of 95 ∘ C for 3 min, 40 cycles of 95 ∘ C for 15 seconds and 60 ∘ C for 1 min. Relative gene expression levels for each sample were calculated using the ΔCT values (normalized detection threshold). Gene expression was analyzed using GAPDH as internal control. FKBP5 baseline expression levels were calculated using ΔCT values and relative to an arbitrarily chosen sample. Results are reported in fold change using the ΔCT values and 2 ΔΔCT method. All samples were run in duplicate.
Quantitative Sanger sequencing to detect allelic imbalance in cDNA
To detect DAE, genomic DNA and RNA were extracted from each of 12 LCLs that were heterozygous for rs1360780 (2); alcohol + heroin (1); cocaine + heroin (3); cocaine + SA (2); cocaine + alcohol + SA (4); alcohol + heroin + SA (1); alcohol + cocaine + heroin + SA (1). For pyrosequencing, four more suitable LCLs became available: one control, rs1360780 GG, CTQ score = 33; three cases: rs1360780 GG, CTQ scores = 65, 91; rs1360780 AA, CTQ score = 67. and rs3800373. To extract genomic DNA, briefly, cells were lysed in 1% SDS, 0.05 M ethylenediaminetetraacetic acid, 50 mM Tris-Cl, pH 8.0, and 100 ng/ml proteinase K, and incubated at 55 ∘ C for 16 h. Genomic DNA was purified by phenol/chloroform extraction. DNA quality and quantity was assessed using a NanoDrop 2000 Spectrophotometer (Thermo Scientific). Methods for extraction of RNA and cDNA synthesis are the same as described above in the Quantitative RT-PCR section. The PCR amplification with primers (Table S1) for FKBP5 was performed using AmpliTaq Gold DNA polymerase (Applied Biosystems), 1 μl of forward and reverse primer (5 μM each), 2 μl of H 2 O at 94 ∘ C for 1 min, followed by 40 cycles each at 94 ∘ C for 20 seconds, 60 ∘ C for 30 seconds, 68 ∘ C for 30 seconds and a final extension step of 72 ∘ C for 10 min. The PCR products were purified using the ExoSAP-IT reagent (Affymetrix, Santa Clara, CA, USA) according to the protocol and sequenced on an Applied Biosystems 3730 DNA Analyzer with Big Dye Terminator Sequencing Mix (Applied Biosystems). To measure DAE in Sanger sequencing electropherograms, the areas under each peak for the G allele and T allele at target positions were measured using IMAGEJ1.46r (National Institutes of Health, http://imagej.nih .gov/ij/). The allele signals from the Sanger cDNA sequencing results were normalized using the allele-specific peak ratios from the Sanger gDNA sequencing. To test if the G allele and T allele were equally expressed, Sanger sequencing data were evaluated by a one-group t-test with values of G allele area/(G allele area + T allele area). The analyses were undertaken using JMP11 software (SAS Institute, Cary, NC, USA).
DNA methylation analysis by bisulfite pyrosequencing
We analyzed DNA methylation of FKBP5 intron 2 including three CpGs and intron 7 including two CpGs in 14 controlsCT− and 19 casesCT+ (Table 1) . These regions were selected according to their spatial and functional relationship to consensus GREs or rs13160780. Genomic DNA was sodium bisulfite converted using the EZ DNA Methylation Kit according to manufacturer's protocol (Zymo Research, Irvine, CA, USA). The DNA methylation of FKBP5 was analyzed by pyrosequencing (EpigenDX, Hopkinton, MA, USA) using primer sets: intron 2 including three CpGs (ADS3136-FS1) and intron 7 including two CpGs (ADS3828-FS2). Methylation-specific pyrosequencing was performed in a single run with numerous internal controls. Each DNA methylation assay was validated for PCR bias and incomplete bisulfite conversion using serial dilutions of in vitro methylated DNA. The percent methylation obtained from the mixing study was highly correlated with the percent of in vitro methylated DNA with r 2 values of >0.95 in each of our assays.
Statistical methods
The rs1360780 AA and AG genotypes were grouped together because both genotypes are equivalent in risk and the AA genotype is at low frequency. The Student's t-test was used for two-group comparisons. The potential effects of covariates (genotype, CT and Dex treatment) on gene expression were tested by analysis of covariance (ANOVAs). All statistical tests were performed JMP 11.0.0.
Results
Differential allelic expression of FKBP5 reporter SNP rs3800373 (G/T)
As seen in Fig. 1 , Dex treatment had no effect on FKBP5 allelic expression in casesCT+ or controlsCT−. ControlsCT− did show a consistently higher G:T allelic expression ratio at baseline (P = 0.001) and after Dex treatment (P = 0.005). However, there was no DAE in casesCT+ (baseline: P = 0.93, Dex treatment: P = 0.69).
Combined effects of rs1360780 and childhood trauma on FKBP5 expression
A two-tailed t test showed that there was a trend effect for increased FKBP5 expression at baseline in casesCT+ relative to controlsCT− (F = 8.9, 27 df, P = 0.056) (Fig. S2) . However, there was no genotype effect. There was a main effect of Dex treatment on FKBP5 expression (F = 98.0, 1 df, P < 0.0001) (Table 2); gene expression was increased more than fivefold in both casesCT+ and controlsCT− after treatment with 100 nM of Dex for 24 h (Fig. 3a) . Also, there was a trend effect of genotype (F = 3.2, 1 df, P = 0.077). Post hoc separate ANCOVAs for casesCT+ and controlsCT− found no effect in controlsCT− (F = 0.06, 1 df, P = 0.81), but a significant genotype effect in casesCT+; the AA/AG risk genotypes had lower FKBP5 induction than GG homozygotes (F = 5.4, 1 df, P = 0.036) (Fig. 2a) . Moreover, among AA/AG genotypes, casesCT+ showed a trend for lower induction of FKBP5 expression relative to controlsCT− (F = 4.38, 1 df, P = 0.055) (Fig. 2a) . Furthermore, regression analysis showed a negative correlation (r = -0.48, P = 0.005) between baseline FKBP5 expression and fold increase of FKBP5 expression after Dex treatment. This finding was detected in casesCT+ (r = −0.50, P = 0.029), and not in controlsCT− (r = −0.38, P = 0.12) (Fig. 2b) .
FKBP4 expression after Dex treatment
FKBP4 has an essential role in nuclear translocation of GR to induce transcription of GR target genes including FKBP5 (Davies et al. 2005) . If FKBP4 expression is changed, expression of FKBP5 could be altered. However, we found no effect of Dex treatment, CT nor FKBP5 rs1360780 genotype on FKBP4 expression ( Table 2 ), suggesting that the low induction of FKBP5 expression in casesCT+ was independent of FKBP4 expression.
Expression of other glucocorticoid-regulated genes after Dex treatment TSC22D3, BIM and RUNX2, known glucocorticoid responsive genes
The expression of TSC22D3 was increased 20-to 30-fold after Dex treatment (F = 129.9, 1 df, P < 0.0001) ( Table 2 , Fig. S3 ). BIM and RUNX2 had lower rates of induction (BIM: F = 33.5, 1 df, P < 0.0001, RUNX2: F = 52.1, 1 df, P < 0.0001) ( Table 2 , Fig. S3 ). However, unlike with FKBP5 there was no effect of rs1360780 genotype or caseCT+/controlCT− status on gene expression (Table 2) .
Correlations between changes in TSC22D3, BIM and RUNX2 after Dex treatment and FKBP5 induction.
There was a significant positive correlation between increased expression in glucocorticoid-regulated genes and FKBP5 in casesCT+ (TSC22D3: r = 0.6, P = 0.01, BIM: r = 0.79, P = 3.0e−4, RUNX2: r = 0.46, P = 0.07) but not in controlsCT− (Fig. 3) . Further analysis showed that in casesCT+, this significant correlation originated from the GG homozygotes (TSC22D3: r = 0.7, P = 0.03, BIM: r = 0.8, P = 0.009, RUNX2: r = 0.79, P = 0.01) and not AA/AG genotypes (Fig. 3) . However, these changes were not correlated with baseline FKBP5 expression (Fig. S4) .
LTF, MSL3L1, PHF21A and ARG1, putative glucocorticoid-regulated genes
The expression of LTF , MSL3L1, ARG1 and PHF21A showed varying results in LCLs of controlsCT− and casesCT+ after Dex treatment (Table 2 , Fig. S5 ). An ANCOVA showed a 1.5-to 2-fold increase in LTF expression after Dex treatment (F = 16.3, 1 df, P = 0.0002) that was independent of genotype (P = 0.65) and caseCT+/controlCT− status (P = 0.50). In contrast, there was decreased MSL3L1 expression after Dex treatment (F = 6.7, 1 df, P = 0.012) but only in controlsCT− (F = 5.5, 1 df, P = 0.02), with no change in casesCT+. ARG1 showed a less than twofold increase in expression (F = 6.2, 1 df, P = 0.016) that was independent of genotype (P = 0.78) and caseCT+/controlCT− status (P = 0.54). Finally, PHF21A showed only a trend change in expression (F = 2.2, 1 df, P = 0.15) and a trend caseCT+/controlCT− effect (F = 3.0, 1 df, P = 0.09). Similar to MSL3L1, this signal derived from controlsCT− that showed decreased expression after Dex treatment, with no change in casesCT+. Therefore, these genes are not highly glucocorticoid-regulated in LCLs.
DNA methylation of FKBP5
We analyzed DNA methylation of FKBP5 intron 2, including three CpGs, and intron 7, including two CpGs. ANCOVAs including all covariates found no effect of Dex treatment, genotype or caseCT+/controlCT− status on DNA methylation at intron 2; CpG1 (F = 0.94, 3 df, P = 0.43), CpG2 (F = 0.74, 3 df, P = 0.53) or CpG3 (F = 0.46, 3 df, P = 0.53) (Table S2 , Fig. 4a ).
There was a trend effect on DNA methylation in intron 7; CpG1: F = 2.36, 3 df, P = 0.08; CpG2: F = 2.24, 3 df, P = 0.09. This contribution was because of the effect of genotype: CpG1: F = 4.6, 1 df, P = 0.04; CpG2: F = 3.5, 1 df, P = 0.07. Post hoc ANCOVAs showed that the CpG1 signal derived from the casesCT+: carriers of the risk AA/AG genotypes had lower methylation than GG homozygotes after Dex treatment (F = 6.8, 1 df, P = 0.02) and at baseline (F = 4.2, 1 df, P = 0.06); the mean differences in methylation were 3.1% and 2.6%, respectively (Fig. 4b) .
Discussion
Previous studies have shown that FKBP5 rs1360780 interacts with CT to predict stress-related disorders such as PTSD and suicidal behavior, including in African Americans (Binder et al. 2008; Roy et al. 2010) . In this study, we investigated different ControlsCT−: n = 13 (AA/AG, n = 9; GG, n = 4) CasesCT+ (patients exposed to CT): n = 16 (AA/AG, n = 7; GG, n = 9).
aspects of the potential functionality of FKBP5 rs1360780 in LCLs from African American men (Roy et al. 2010 ): a group of casesCT+ who were substance-dependent patients who had experienced high CT and a group of controlsCT−, free of substance dependence and suicidal behavior, who had not been exposed to CT. Importantly, the casesCT+ had not only experienced trauma but also had suffered psychiatric disease, on average two substance addictions. Nearly all the earlier studies have performed analyses in peripheral blood cells (PBCs). However, in this study we used LCLs derived from PBCs transformed with Epstein Barr virus and maintained in culture for a minimum of 50 passages. We investigated DAE, the combined influences of genotype and CT on FKBP5 expression at baseline and after GR stimulation, the influence of FKBP5 rs1360780 on other glucocorticoid-regulated genes after GR stimulation and the influence of genotype and CT on DNA methylation at the intron 2 and intron 7 regulatory regions of FKBP5. As discussed below, other than the results for DAE, all the significant findings were in casesCT+ and not controlsCT−. Importantly, for the design and interpretation of DAE analyses, there is high LD across FKBP5 including between rs1360780 (A/G) and rs3800373 (G/T) (Bevilacqua et al. 2012; Binder et al. 2004; Huang et al. 2014; Roy et al. 2010 ). This , RUNX2 ) and FKBP5 expression is dependent on CT exposure and rs1360780 genotype. CasesCT+ n = 16: AA/AG n = 7, GG n = 9; ControlsCT− n = 13: AA/AG n = 9, GG n = 4.
haplotype has been associated with differential induction of FKBP5 mRNA and protein by GR activation (Binder et al. 2004) and with GR resistance such that A allele carriers of healthy controls have a prolonged cortisol response even to minor stressors (Ising et al. 2008) . Potential functionality of rs1360780 was shown by an assay in HeLa cells with luciferase gene constructs encompassing the consensus GRE site together with either the rs1360780 A risk allele or the G protective allele; after Dex treatment the luciferase activity of the construct with the A allele was higher than that of the G allele (Klengel et al. 2013) . Our study has shown allele-specific differences in FKBP5 expression in the LCLs ControlsCT−: n = 14 (AA/AG, n = 9; GG, n = 5) CasesCT+ (patients exposed to CT): n = 19 (AA/AG, n = 8; GG, n = 11). Dex− = baseline; Dex+ = treatment with dexamethasone. Data are shown as mean ± SE. *P < 0.05. P-values were from ANCOVAs followed by post hoc test.
of controlsCT−, but not casesCT+. ControlsCT− had a higher A:G, risk:protective allelic expression ratio both at baseline and after Dex treatment. This suggests that the haplotype including the rs3800373 G allele and the rs1360780 A risk allele has a cis-acting functional locus affecting FKBP5 expression and the functionality might be disturbed by cellular long-term memory associated with CT. However, because of the high LD across the gene it remains possible that other unknown functional SNPs, other than rs1360780 might be responsible for the DAE.
The balance between FKBP5 expression and GR activation is a key component of an ultra-short negative-feedback mechanism. The GR activation directly induces FKBP5 transcription (Vermeer et al. 2003) . After rapid induction of FKBP5 in response to GR activation, FKBP5 binds to the GR, reduces the affinity of GR for cortisol and decreases translocation of the GR to the nucleus (Vermeer et al. 2003; Zannas & Binder 2014) . Our study investigated elements of this negative-feedback loop, and the effects of CT and the cis-acting FKBP5 locus on it. At baseline, there was a trend for casesCT+ to have higher FKBP5 expression than controlsCT−. The GR stimulation increased expression in both groups. However, A risk allele carriers, who were casesCT+, showed strong sensitivity to GR stimulation compared with GG homozygotes, whereas there was no genotype effect in controlsCT−. In casesCT+, there was a negative correlation between baseline FKBP5 expression and fold change increase in expression after GR stimulation, suggesting a ceiling effect. This finding was not detected in controlsCT−, perhaps because they had lower baseline FKBP5 expression. This suggests that casesCT+ may be more vulnerable to future stress because they have already maximal compensated elevation of FKBP5 expression. The interactive effect of the FKBP5 A risk allele and CT exposure appears to lead to lower FKBP5 induction after GR stimulation and therefore a 'dampening' of the negative-feedback mechanism. Moreover, a significant positive correlation was observed after GR stimulation between induction of FKBP5 and induction of known glucocorticoid-regulated genes, TSC22D3, BIM and RUNX2, only in the GG homozygotes, who were casesCT+ and not in controlsCT−. These results suggest that CT interacts with the FKBP5 risk genotype to alter the function of the ultra-short feedback and downstream expression of glucocorticoid-regulated genes.
Accumulating evidence indicates that CT may exert long-lasting effects through epigenetic changes (Lutz & Turecki 2014; Szyf 2011 ). An earlier study of FKBP5 DNA methylation in PBCs of adults showed that CT was associated with hypomethylation in intron 7 (Klengel et al. 2013) . Moreover, there was a negative correlation between DNA methylation and CTQ scores in the rs1360780 A risk allele carriers, but not GG carriers. The PBCs differ from LCLs, nevertheless we observed a similar genotypic difference in DNA methylation at CpG1 of intron 7; Klengel's group observed a 12% decrease in methylation of A allele carriers relative to GG carriers among casesCT+. Likewise, we observed an approximately 4% decrease in methylation of A allele carriers in casesCT+. Also, the percentages of DNA methylation in our study of CpG2 (85-90%) of intron 7 and CpGs (CpG1: 78-82%; CpG2: ≈70%) of intron 2 were consistent with methylation percentages in the previous report (Klengel et al. 2013) . This commonality suggests that CT may lead to allele-specific epigenetic changes with a decrease in DNA methylation as measured in PBCs as well as LCLs. There have been concerns that several factors could potentially affect DNA methylation patterns in LCLs compared to the original B lymphocytes including Epstein-Barr virus infection, cell culture conditions and freezing cycles. Several studies examined global methylation levels and concluded that LCLs are non-equivalent to PBCs (Sugawara et al. 2011; Thompson et al. 2013) . However, most of the promoter methylation regions in PBCs were maintained in LCLs (Sugawara et al. 2011) and studies in individual genes have shown limited variability (Brennan et al. 2009; Saferali et al. 2010) . For example, Brennan and colleagues looked at 318 genes in LCL and PBC sample pairs and identified only 8% of genes with different methylation profiles. It is possible that our finding of a smaller difference in DNA methylation of intron 7 relative to the previous study (Klengel et al. 2013 ) may be because of the effect of the Epstein-Barr Virus transformation or long-term culture.
There are several limitations to our study. The sample sizes of LCLs from casesCT+ and controlsCT− were small, and therefore some of the negative results may be false. Nevertheless, our significant data reproduced results from other studies, e.g. intron 7 methylation results (Klengel et al. 2013) . However, it is not clear whether the small difference in DNA methylation (12% in blood and 4% in LCLs) between A allele carriers and GG carriers affects gene expression. It may that LCLs have a different array of potential factors affecting gene regulation than is found in PBCs. Although exposing cells to 100 nM dex for 24 h is a commonly used protocol for treatment of cell lines, it is possible that by this time protein levels of FKBP5 may already feedback on RNA expression. In our study, we have compared casesCT+ with healthy controlsCT−. It should be noted that the casesCT+ who have a minimum of two diagnoses of substance dependence and suicidal behavior, may have had many other sources of trauma or other significant environmental exposures. The casesCT+ might also have been more likely to share other liability alleles, but it was impractical for us to evaluate this because of the size of the sample. Our study included only men and regulation of stress response genes may differ in women.
In conclusion, our study clearly showed cis and trans effects of rs1360780 on gene regulation and combined effects with exposure to CT. The overall conclusion of our study and the previous study (Klengel et al. 2013 ) is that CT might be imprinted in cellular memory and, in combination with genetic effects, might induce abnormal GR responses to stress. Institute on Drug Abuse, NIH. The authors declare no conflict of interest.
Supporting Information
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